Co-encapsulation of bioengineered IGF-II-producing cells and pancreatic islets: effect on beta-cell survival

Jourdan, Guillaume; Dusseault, Julie; Benhamou, Pierre Yves; Rosenberg, Lawrence; Hallé, Jean‐Pierre

doi:10.1038/gt.2010.166

Cited by 26 publications

(13 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…22 IGF-II coencapsulation with rodent pancreatic islet cells has also been demonstrated to improve beta cell survival. 23 It is possible to speculate that IGF-II and IGFBP-2 have favourable effects on HDL cholesterol mediated through an increase in insulin sensitivity.…”

Section: 6mentioning

confidence: 99%

Insulin-like growth factor-II and insulin-like growth factor binding protein-2 prospectively predict longitudinal elevation of HDL-cholesterol in type 2 diabetes

Narayanan

Oliver

et al. 2013

Ann Clin Biochem

View full text Add to dashboard Cite

Introduction: Associations of insulin-like growth factor-II (IGF-II) and insulin-like growth factor binding protein-2 (IGFBP-2) with cardiovascular risk have been inadequately studied. We hypothesized that IGF-II and IGFBP-2 associate with longitudinal trends in lipid profiles in type 2 diabetes patients. Subjects and methods: Four hundred and eighty nine subjects with type 2 diabetes (age 27-87 years) from the Salford Diabetes Cohort were studied. Longitudinal clinical information was extracted for an eight-year period (2002)(2003)(2004)(2005)(2006)(2007)(2008)(2009) from an integrated electronic dataset of primary care and hospital data. Results: There were 294 male subjects and mean age was 62.9 years. At baseline, IGF-II concentration was 602 ng/mL. HDL cholesterol at baseline was associated with log-IGF-II concentration in a model adjusted for age, gender, baseline body-mass index (BMI), estimated glomerular filtration rate (eGFR) and lipid-lowering therapy. IGFBP-1 and IGFBP-2 were associated with high HDL-cholesterol. A higher circulating IGF-II concentration at baseline was also associated with longitudinal increase in HDL-cholesterol in mixed-effects regression analyses independent of IGF-I, IGFBP-1, IGFBP-2, IGFBP-3, age, gender, eGFR, BMI and lipid-lowering therapy. Log-transformed baseline concentrations of IGFBP-1 and IGFBP-2 were also associated with longitudinal elevation in HDL-cholesterol. No association was observed for IGF-II or IGFBP-2 with longitudinal LDL cholesterol trends. Conclusion: Our analyses based on 'real world' data demonstrate that higher baseline IGF-II and IGFBP-2 predict increased HDL concentration over time, implicating IGF-II in modulation of circulating HDL-cholesterol concentrations.

show abstract

Section: 6mentioning

confidence: 99%

Insulin-like growth factor-II and insulin-like growth factor binding protein-2 prospectively predict longitudinal elevation of HDL-cholesterol in type 2 diabetes

Narayanan

Oliver

et al. 2013

Ann Clin Biochem

View full text Add to dashboard Cite

show abstract

“…Importantly, the cells displayed no loss of glucose responsiveness, a critical function that ordinarily disappears very early during apoptosis. Combining this cytokine-resistant selection strategy with a cell line overexpressing IGF2, such as that used by Jourdan et al (2011), could provide a novel approach for improving islet cell survival in the early post-transplant period.…”

Section: Apoptosis In Islet Transplantation: the Role For Pro-inflammmentioning

confidence: 99%

“…IGF2 has been shown to promote pancreatic b-cell survival against apoptotic stimuli in vitro and in vivo (Rabinovitch et al 1982, Swenne et al 1987, Hogg et al 1993, Ilieva et al 1999, Robitaille et al 2003, Jourdan et al 2011 and induce proliferation in a growth-arrested mouse b-cell line (Milo-Landesman & Efrat 2002). IGF2 protects pre-diabetic NOD mouse islets from the cytotoxic actions of IL1b by the mechanisms that include a reduction in apoptosis (Hill et al 1999b).…”

Section: Apoptosis In Islet Transplantation: the Role For Pro-inflammmentioning

confidence: 99%

“…In one strategy, bioengineered TM4 cells stably overexpressing IGF2 were coencapsulated with islet cells into alginate microcapsules, leading to significantly improved islet survival in vitro and in vivo, and improved normoglycemia maintenance (Jourdan et al 2011). Since their introduction over 30 years ago, significant advances have been made in the engineering of alginate microcapsules including refinement of their sophisticated multilayer architectures leading to enhanced biocompatibility and biodegradability in vivo (Schneider et al 2001).…”

Section: Apoptosis In Islet Transplantation: the Role For Pro-inflammmentioning

confidence: 99%

“…In comparison, IGF2 exerts a robust anti-apoptotic effect on many cell and tissue types including neurons, ovarian pre-ovulatory cells and pancreatic islets (Jung et al 1996, Stewart & Rotwein 1996, Petrik et al 1998. Jourdan et al (2011) have shown the usefulness of IGF2 as an islet survival factor in a rodent model of islet engraftment, and transgenic overexpression of IGF2 protects against pro-inflammatory cytokineinduced apoptosis in vitro and improves islet transplant outcomes in vivo (Hughes et al 2013), a process mediated via the interaction of IGF2 with the IGF1 receptor (IGF1R) on the islet cell surface. For these reasons, we believe that IGF2 represents the more promising endocrine growth factor to improve islet transplant survival.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

IGF2: an endocrine hormone to improve islet transplant survival

Hughes¹,

Rojas-Canales²,

Drogemuller³

et al. 2014

Journal of Endocrinology

View full text Add to dashboard Cite

In the week following pancreatic islet transplantation, up to 50% of transplanted islets are lost due to apoptotic cell death triggered by hypoxic and pro-inflammatory cytokinemediated cell stress. Thus, therapeutic approaches designed to protect islet cells from apoptosis could significantly improve islet transplant success. IGF2 is an anti-apoptotic endocrine protein that inhibits apoptotic cell death through the mitochondrial (intrinsic pathway) or via antagonising activation of pro-inflammatory cytokine signalling (extrinsic pathway), in doing so IGF2 has emerged as a promising therapeutic molecule to improve islet survival in the immediate post-transplant period. The development of novel biomaterials coated with IGF2 is a promising strategy to achieve this. This review examines the mechanisms mediating islet cell apoptosis in the peri-and post-transplant period and aims to identify the utility of IGF2 to promote islet survival and enhance long-term insulin independence rates within the setting of clinical islet transplantation.

show abstract

Differentiation of microfluidic‐encapsulated trabecular meshwork mesenchymal stem cells into insulin producing cells and their impact on diabetic rats

Barati

Nadri

Hajian

et al. 2018

Journal Cellular Physiology

View full text Add to dashboard Cite

Tissue and stem cell encapsulation andtransplantation were considered as promising tools in the treatment of patients with diabetes mellitus. The aim of this study was to evaluate the effect of microfluidic encapsulation on the differentiation of trabecular meshwork mesenchymal stem cells (TM-MSC), into insulin-producing cells (IPCs) both in vitro and in vivo. The presence of differentiated cells in microfibers (three dimensional [3D]) and tissue culture plates (TCPS; two dimensional [2D]) culture was evaluated by detecting mRNA and protein expression of pancreatic islet-specific markers as well as measuring insulin release of cells in response to glucose challenges.Finally, semi-differentiated cells in microfibers (3D) and 2D cultures were used to control the glucose level in diabetic rats. The results of this study showed that MSCs differentiated in alginate microfibers (fabricated by microfluidic device) express more Pdx-1 mRNA (1.938-fold, p-value: 0.0425) and Insulin mRNA (2.841-fold, p-value: 0.0001) compared with those cultured on TCPS. Furthermore, cell encapsulation in microfluidic derived microfibers decreased the level of blood glucose in diabetic rats.The approach used in this study showed the possibility of alginate microfibers as a matrix for differentiation of TM-MSCs (as a new source) into IPCs. In addition, it could minimize different steps in stem cell differentiation, handling, and encapsulation, which lead to loss of an unlimited number of cells. K E Y W O R D S diabetes mellitus, encapsulation, insulin-producing cells (IPCs), microfluidics, trabecular meshwork mesenchymal stem cells (TM-MSCs)

show abstract

Co-encapsulation of bioengineered IGF-II-producing cells and pancreatic islets: effect on beta-cell survival

Cited by 26 publications

References 34 publications

Insulin-like growth factor-II and insulin-like growth factor binding protein-2 prospectively predict longitudinal elevation of HDL-cholesterol in type 2 diabetes

Insulin-like growth factor-II and insulin-like growth factor binding protein-2 prospectively predict longitudinal elevation of HDL-cholesterol in type 2 diabetes

IGF2: an endocrine hormone to improve islet transplant survival

Differentiation of microfluidic‐encapsulated trabecular meshwork mesenchymal stem cells into insulin producing cells and their impact on diabetic rats

Contact Info

Product

Resources

About